Presentation of Vepdegestrant Data
Arvinas, Inc. (NASDAQ: ARVN) is set to present significant findings related to its investigational drug, vepdegestrant, at the European Society for Medical Oncology Congress. This event takes place in Berlin, from October 17 to 21, where new patient-reported outcomes from the Phase 3 VERITAC-2 trial will be shared.
Details of the Clinical Study
The first presentation will focus on the comparison of patient-reported outcomes (PROs) between vepdegestrant and fulvestrant, specifically in patients with estrogen receptor 1 gene mutations and advanced breast cancer. Dr. Mario Campone will serve as the presenting author during a mini oral session, scheduled for October 20, at 11:25 CEST.
Presentation Highlights
Entitled "Patient-reported outcomes (PROs) with vepdegestrant (VEP) vs fulvestrant (FUL) in patients (pts) with estrogen receptor (ER) 1 gene mutated (ESR1m) ER+/HER2? advanced breast cancer in the phase 3 VERITAC-2 trial," this report aims to showcase the potential efficacy of vepdegestrant. Presentation Number 489MO will provide insights into how this novel treatment method compares to existing therapy.
Second Study Presented
Additionally, another abstract will explore a phase 2 study of neoadjuvant vepdegestrant, comparing it with anastrozole in postmenopausal patients with localized breast cancer. This session will take place on October 19, with Dr. Peter A. Fasching as the presenting author.
About Vepdegestrant
Vepdegestrant is a unique PROTAC estrogen receptor degrader under development by Arvinas, designed to treat patients with estrogen receptor-positive breast cancer possessing specific genetic mutations. This work is part of Arvinas' expanding portfolio of innovative therapies targeting unmet medical needs for cancer patients.
Collaboration with Pfizer
In July 2021, Arvinas announced a significant partnership with Pfizer to co-develop and commercialize vepdegestrant. In an important update in September 2025, both companies revealed their intention to seek a third-party partner for the out-licensing and commercialization of this promising drug.
FDA's Endorsement
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for vepdegestrant as a monotherapy for adults with estrogen receptor-positive, HER2-negative breast cancer. This designation, coupled with the FDA's Fast Track status, underlines the potential of vepdegestrant to become a preferred treatment option for patients who have undergone prior endocrine therapy.
About Arvinas, Inc.
Headquartered in New Haven, Connecticut, Arvinas (NASDAQ: ARVN) focuses on developing transformative therapies for patients with serious diseases. Utilizing its proprietary PROTAC technology, the company aims to revolutionize how therapies are delivered, with several investigational drugs undergoing clinical trials targeting key oncological and neurodegenerative conditions.
Frequently Asked Questions
What is vepdegestrant?
Vepdegestrant is an investigational drug designed as a PROTAC estrogen receptor degrader, targeting specific mutations in breast cancer.
When will the data from the clinical trials be presented?
The data will be presented during the European Society for Medical Oncology Congress, from October 17 to 21.
Who is leading the presentations at the Congress?
Dr. Mario Campone will present the findings from the VERITAC-2 trial.
What does the collaboration with Pfizer involve?
The partnership with Pfizer focuses on the co-development and commercialization of vepdegestrant.
What is the FDA's stance on vepdegestrant?
The FDA has accepted the NDA for vepdegestrant and granted it Fast Track designation.
